Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPLP1 | P05386 | 2/20 | 0.42 |
| ▸ | RPLP0 | P05388 | 2/20 | 0.42 |
| ▸ | RPS17 | P08708 | 2/20 | 0.42 |
| ▸ | RPSA | P08865 | 2/20 | 0.42 |
| ▸ | RPS2 | P15880 | 2/20 | 0.42 |
| ▸ | RPL35A | P18077 | 2/20 | 0.42 |
| ▸ | RPL7 | P18124 | 2/20 | 0.42 |
| ▸ | RPL17 | P18621 | 2/20 | 0.42 |
| ▸ | RPS4Y1 | P22090 | 2/20 | 0.42 |
| ▸ | RPS3 | P23396 | 2/20 | 0.42 |
| ▸ | RPS12 | P25398 | 2/20 | 0.42 |
| ▸ | RPL13 | P26373 | 2/20 | 0.42 |
| ▸ | RPL10 | P27635 | 2/20 | 0.42 |
| ▸ | RPL12 | P30050 | 2/20 | 0.42 |
| ▸ | RPL9; RPL9P7; RPL9P8; RPL9P9 | P32969 | 2/20 | 0.42 |
| ▸ | RPL22 | P35268 | 2/20 | 0.42 |
| ▸ | RPL4 | P36578 | 2/20 | 0.42 |
| ▸ | RPS19 | P39019 | 2/20 | 0.42 |
| ▸ | RPL3 | P39023 | 2/20 | 0.42 |
| ▸ | RPL13A | P40429 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870950 | 0.91 | OPRD1 (0.41) | KCNH2OPRM1OPRD1SLC6A2SLC6A4 | |
| SCHEMBL7976675 | 0.85 | OPRD1 (0.35) | OPRM1OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5870905 | 0.82 | CHRM1 (0.41) | OPRD1CHRM1CHRM3CHRM2 | |
| SCHEMBL5871033 | 0.81 | OPRD1 (0.44) | KCNH2OPRM1OPRD1SLC6A2SLC6A4 | |
| SCHEMBL7503837 | 0.81 | OPRD1 (0.44) | KCNH2OPRM1OPRD1SLC6A2SLC6A4 | |
| SCHEMBL7498243 | 0.81 | OPRD1 (0.44) | KCNH2OPRM1OPRD1SLC6A2SLC6A4 | |
| SCHEMBL5871054 | 0.80 | CHRM2 (0.39) | KCNH2OPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5870866 | 0.80 | OPRM1 (0.41) | KCNH2OPRM1OPRD1SLC6A2SLC6A4 | |
| SCHEMBL7501264 | 0.79 | OPRD1 (0.42) | KCNH2OPRM1OPRD1SLC6A3CHRM1 | |
| SCHEMBL3273608 | 0.79 | TRPM8 (0.46) | KCNH2OPRM1OPRD1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129228-B2 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | CUNY GREGORY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-6677332-B1 | AMIDE-SUBSTITUTED PIPERIDINE OR AZEPINE DERIVATIVES TO TREAT DRUG ABUSE AND TINNITUS | SEPRACOR, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6645980-B1 | Ligands for biological receptors such as opiate receptors or G-protein coupled receptors used for treating pain, drug dependence or tinnitus in mammals | SEPRACOR INC. | 2003-11-11 | — | — | US | disclosed |
| US-6635661-B2 | Piperidinyl amide compounds | SEPRACOR INC. | 2003-10-21 | — | — | US | disclosed |
| WO-2002069895-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1187810-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001092226-A1 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF | SEPRACOR, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2000071518-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | RPLP1 1409/4885RPLP0 2607/4885RPS17 2914/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | RPLP1 1409/4885RPLP0 2607/4885RPS17 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.